Pflug Koory LLC Buys 336 Shares of Thermo Fisher Scientific Inc. $TMO

Pflug Koory LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,369 shares of the medical research company’s stock after buying an additional 336 shares during the quarter. Thermo Fisher Scientific comprises 1.1% of Pflug Koory LLC’s portfolio, making the stock its 16th biggest holding. Pflug Koory LLC’s holdings in Thermo Fisher Scientific were worth $2,177,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. NTV Asset Management LLC grew its position in shares of Thermo Fisher Scientific by 0.7% during the second quarter. NTV Asset Management LLC now owns 4,132 shares of the medical research company’s stock worth $1,675,000 after purchasing an additional 30 shares in the last quarter. 111 Capital grew its holdings in Thermo Fisher Scientific by 150.1% during the 2nd quarter. 111 Capital now owns 8,261 shares of the medical research company’s stock valued at $3,350,000 after buying an additional 4,958 shares in the last quarter. Tilia Fiduciary Partners Inc. grew its holdings in Thermo Fisher Scientific by 10.1% during the 2nd quarter. Tilia Fiduciary Partners Inc. now owns 4,534 shares of the medical research company’s stock valued at $1,838,000 after buying an additional 415 shares in the last quarter. ZWJ Investment Counsel Inc. boosted its holdings in shares of Thermo Fisher Scientific by 6.1% in the 2nd quarter. ZWJ Investment Counsel Inc. now owns 82,548 shares of the medical research company’s stock worth $33,470,000 after purchasing an additional 4,778 shares during the period. Finally, Barrett & Company Inc. boosted its holdings in shares of Thermo Fisher Scientific by 377.4% in the 2nd quarter. Barrett & Company Inc. now owns 253 shares of the medical research company’s stock worth $103,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 3.6%

Shares of NYSE:TMO opened at $543.88 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The business’s fifty day simple moving average is $482.58 and its 200-day simple moving average is $447.76. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $205.37 billion, a PE ratio of 31.46, a P/E/G ratio of 2.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. William Blair initiated coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. HSBC reissued a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target for the company in a research note on Friday, July 11th. Finally, UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $585.37.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.